167 related articles for article (PubMed ID: 25639366)
41. Breast cancer resistance protein (BCRP/ABCG2).
Staud F; Pavek P
Int J Biochem Cell Biol; 2005 Apr; 37(4):720-5. PubMed ID: 15694832
[TBL] [Abstract][Full Text] [Related]
42. Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance.
Bruhn O; Cascorbi I
Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1337-54. PubMed ID: 25162314
[TBL] [Abstract][Full Text] [Related]
43. Genetic and Dietary Regulation of Glyburide Efflux by the Human Placental Breast Cancer Resistance Protein Transporter.
Bircsak KM; Gupta V; Yuen PY; Gorczyca L; Weinberger BI; Vetrano AM; Aleksunes LM
J Pharmacol Exp Ther; 2016 Apr; 357(1):103-13. PubMed ID: 26850786
[TBL] [Abstract][Full Text] [Related]
44. Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo.
Ceckova M; Libra A; Pavek P; Nachtigal P; Brabec M; Fuchs R; Staud F
Clin Exp Pharmacol Physiol; 2006; 33(1-2):58-65. PubMed ID: 16445700
[TBL] [Abstract][Full Text] [Related]
45. Pharmacogenomic importance of ABCG2.
Cusatis G; Sparreboom A
Pharmacogenomics; 2008 Aug; 9(8):1005-9. PubMed ID: 18681776
[TBL] [Abstract][Full Text] [Related]
46. Interindividual variability in the hepatic expression of the human breast cancer resistance protein (BCRP/ABCG2): effect of age, sex, and genotype.
Prasad B; Lai Y; Lin Y; Unadkat JD
J Pharm Sci; 2013 Mar; 102(3):787-93. PubMed ID: 23280364
[TBL] [Abstract][Full Text] [Related]
47. Synergistic interaction of ABCB1 and ABCG2 polymorphisms predicts the prevalence of toxic encephalopathy during anticancer chemotherapy.
Erdilyi DJ; Kámory E; Csókay B; Andrikovics H; Tordai A; Kiss C; Filni-Semsei A; Janszky I; Zalka A; Fekete G; Falus A; Kovács GT; Szalai C
Pharmacogenomics J; 2008 Oct; 8(5):321-7. PubMed ID: 17938643
[TBL] [Abstract][Full Text] [Related]
48. ABCG2 polymorphisms, 34G>A and 421C>A in a Korean population: analysis and a comprehensive comparison with other populations.
Kim KA; Joo HJ; Park JY
J Clin Pharm Ther; 2010 Dec; 35(6):705-12. PubMed ID: 21054463
[TBL] [Abstract][Full Text] [Related]
49. Acyclovir is a substrate for the human breast cancer resistance protein (BCRP/ABCG2): implications for renal tubular transport and acyclovir-induced nephrotoxicity.
Gunness P; Aleksa K; Koren G
Can J Physiol Pharmacol; 2011 Sep; 89(9):675-80. PubMed ID: 21859328
[TBL] [Abstract][Full Text] [Related]
50. Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survival.
Suvannasankha A; Minderman H; O'Loughlin KL; Nakanishi T; Ford LA; Greco WR; Wetzler M; Ross DD; Baer MR
Br J Haematol; 2004 Nov; 127(4):392-8. PubMed ID: 15521915
[TBL] [Abstract][Full Text] [Related]
51. Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype.
Sparreboom A; Gelderblom H; Marsh S; Ahluwalia R; Obach R; Principe P; Twelves C; Verweij J; McLeod HL
Clin Pharmacol Ther; 2004 Jul; 76(1):38-44. PubMed ID: 15229462
[TBL] [Abstract][Full Text] [Related]
52. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y
J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939
[TBL] [Abstract][Full Text] [Related]
53. Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2).
Merino G; Jonker JW; Wagenaar E; Pulido MM; Molina AJ; Alvarez AI; Schinkel AH
Drug Metab Dispos; 2005 May; 33(5):614-8. PubMed ID: 15703302
[TBL] [Abstract][Full Text] [Related]
54. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter.
Volk EL; Schneider E
Cancer Res; 2003 Sep; 63(17):5538-43. PubMed ID: 14500392
[TBL] [Abstract][Full Text] [Related]
55. Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro.
Storch CH; Ehehalt R; Haefeli WE; Weiss J
J Pharmacol Exp Ther; 2007 Oct; 323(1):257-64. PubMed ID: 17652262
[TBL] [Abstract][Full Text] [Related]
56. Interactions between riluzole and ABCG2/BCRP transporter.
Milane A; Vautier S; Chacun H; Meininger V; Bensimon G; Farinotti R; Fernandez C
Neurosci Lett; 2009 Mar; 452(1):12-6. PubMed ID: 19146924
[TBL] [Abstract][Full Text] [Related]
57. Determinants of the activity and substrate recognition of breast cancer resistance protein (ABCG2).
Szafraniec MJ; Szczygieł M; Urbanska K; Fiedor L
Drug Metab Rev; 2014 Nov; 46(4):459-74. PubMed ID: 25036722
[TBL] [Abstract][Full Text] [Related]
58. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs.
Ieiri I; Higuchi S; Sugiyama Y
Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):703-29. PubMed ID: 19442037
[TBL] [Abstract][Full Text] [Related]
59. Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass.
Bruyère A; Declèves X; Bouzom F; Ball K; Marques C; Treton X; Pocard M; Valleur P; Bouhnik Y; Panis Y; Scherrmann JM; Mouly S
Mol Pharm; 2010 Oct; 7(5):1596-607. PubMed ID: 20604570
[TBL] [Abstract][Full Text] [Related]
60. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.
Breedveld P; Zelcer N; Pluim D; Sönmezer O; Tibben MM; Beijnen JH; Schinkel AH; van Tellingen O; Borst P; Schellens JH
Cancer Res; 2004 Aug; 64(16):5804-11. PubMed ID: 15313923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
